A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database

BackgroundProton pump inhibitors (PPIs) are effective treatments for acid-related disorders but may pose tumor risks with long-term use. Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. This study aims to comprehensively analyze the relationship between PPI...

Full description

Bibliographic Details
Main Authors: Ya-Jun Zhang, Dan-Dan Duan, Qian-Yu Tian, Cai-E. Wang, Shu-Xun Wei
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
proton pump inhibitors
tumor adverse events
FAERS
disproportionality analysis
pharmacovigilance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1524903/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1524903/full

Similar Items